glp 1 drugs for weight loss oral Comparing Ozempic, Wegovy and Other GLP-1 Feel fuller GLP-1 Weight-Loss Pills: What You

Why Multi-Receptor Agonists Are a Game-Changer for Adolescent Obesity Despite the success of GLP-1 monotherapy, dual and triple agonists offer significant advantages in obesity treatment by engaging multiple hormonal pathways

Diabetes 49 (5), 741748

Key Takeaways Retatrutide (LY3437943) is an investigational weight loss medication developed by Eli Lilly Triple-agonist mechanism: First drug to activate GLP-1, GIP, and glucagon receptors simultaneously Phase 2 results: Up to 24.2% weight loss at 48 weeks (approximately 58 lbs for a 240-lb person) Not FDA-approved: Currently in Phase 3 clinical trials, expected approval in 20272028 How it differs: Outperforms semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) in weight loss trials Access now: Clinical trials (free), compounding pharmacies, or research peptide vendors What Is Retatrutide

Gilbert, Rosenthal, March 2024

increased risk of kidney, pancreas and gastrointestinal problems Getty Images Demand for weight-loss medications sold under brand names such as Ozempic and Wegovy continues to surge, with a recent study reporting one in eight Americans has taken or is currently using the drugs to treat diabetes, heart disease or obesity